The ingredient from CK Nutraceuticals is a patented blend of Angelica gigas, Cynanchum wilfordii, and Phlomis umbrosa.
EstroG-100, a patented herbal-blend ingredient from CK Nutraceuticals (Oakville, ON, Canada), was shown in a recent study to support numerous symptoms associated with menopause. The ingredient is a patented blend of Angelica gigas, Cynanchum wilfordii, and Phlomis umbrosa, all of which the company says have a safe history of use in Chinese medicine.
The 12-week study1, published in HSOA Journal of Reproductive Medicine, Gynecology & Obstetrics, was a multicenter, randomized, double-blind, placebo-controlled trial in 105 women aged 40-70 with menopausal symptoms. The subjects were given either EstroG-100 or a placebo daily. At the end of the study, researchers found that EstroG-100 subjects demonstrated statistically significant improvements Kupperman Menopausal Index (KMI) scores, a measure of menopausal symptoms, compared to the control group. EstroG-100 subjects showed improvements in paresthesia (numbness), nervousness, melancholia, vertigo, fatigue, arthralgia and myalgia, formication, and fatigue. The researchers concluded that “EstroG-100 was demonstrated to be a safe and effective natural material for improving the quality of life of perimenopausal women by alleviating various menopausal symptoms, thus supporting the results of previous studies.”
CK Nutraceuticals says that clinical trials have shown that EstroG-100 can improve hot flashes/night sweats, rheumatic pain such as in the joints, vaginal dryness, and insomnia, among other menopause-related symptoms. In Canada, for instance, key structure-function claims for the product include “helps support mood balance during menopause” and “helps to relieve the symptoms associated with menopause such as hot flashes, night sweats, paresthesia, insomnia, nervousness, vertigo, fatigue, rheumatic pain, and vaginal dryness.”
Reference
Nutritional Outlook's Women in Nutraceuticals Roundtable: The Future of Women's Health Research
July 19th 2024Watch "The Future of Women's Health Research," a roundtable discussion presented by Nutritional Outlook in partnership with Women in Nutraceuticals. This roundtable is supplement to a recent article commissioned by WIN and published by Nutritional Outlook, titled “Taking Initiative: Can the WHI’s model help the nutraceutical industry answer questions the study didn’t even ask?”
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.